Synsorb releases SynsorbCd Phase II data

Synsorb (TSE:SYB; SYBB) said SynsorbCd reduced recurrence of Clostridium difficile-associated disease versus placebo, although this did not reach statistical significance. Of 86 evaluable patients in ...